IRCT20180404039187N14 IRCT 2025-06-06 Research Vice-chancellor The efficacy of piracetam on children with global developmental delay The efficacy of piracetam on children with global developmental delay 2025-01-19 anticipated 40 Complete https://irct.ir/trial/78121 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. N/A global developmental delay. In this study, 40 patients with developmental delay in more than or equal to 2 developmental areas are selected from among the patients referred to the pediatric neurology clinics and the Comprehensive Child Development Center. For these patients, after obtaining informed consent, the Iranian brand Piracetam syrup with the same name, Piracetam, is prescribed at a dose of 40 mg/kg/day once daily. Piracetam belongs to the racetam group, with the chemical name 2-oxo-1-pyrrolidine acetamide. This drug is a cyclic derivative of the neurotransmitter GABA and has the same 2-oxo-pyrrolidone basic structure as pyroglutamic acid. Piracetam is a positive allosteric modulator of the AMPA receptor, acting on ion channels or ion carriers, resulting in increased neuronal excitability. Piracetam affects NMDA glutamate receptors, which are involved in learning and memory processes, through muscarinic cholinergic receptors (ACh), which are involved in memory processes. This drug has been shown to increase oxygen consumption in the brain. The mother is given an age-appropriate ASQ form and is advised to practice, repeat, and teach the age-appropriate activities on the form with her child. Three months later, and six months after starting piracetam, the ASQ forms are completed by the same individual, and their results are compared with those on the previous forms. An improvement in the ASQ score of more than one standard deviation (SD) is considered a response to treatment.. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information